53 -11 (83) 2025 - Ortikboev J.O. - OPTIMIZATION OF METHODS FOR PREVENTING THE PROGRESSION OF THE CLINICAL COURSE OF CHRONIC KIDNEY DISEASE

Resume: A prospective randomized open-label controlled trial was conducted, which included 150 patients with CKD stages 3-4 (GFR 15-59 ml/min/1.73 m2). The patients were randomized into 2 groups: the main group (n=75), which received an optimized program (an individualized low-protein diet of 0.6-0.8 g/kg/day under the control of nutritional status, strict blood pressure control (<130/80 mmHg) with priority of ace inhibitors/ARBs, correction of phosphorus-calcium metabolism, anemia treatment, the patient's school), and a comparison group (n=75) who received standard therapy according to national guidelines. The follow-up period was 24 months. The main criterion of effectiveness was the rate of decrease in glomerular filtration rate (GFR, ml/min/1.73 m2/year). Additional criteria included the dynamics of proteinuria, serum albumin levels, and the frequency of achieving target blood pressure, phosphorus, and hemoglobin levels.

Key words: Keywords: chronic kidney disease, progression, prevention, glomerular filtration rate, proteinuria, arterial hypertension, diet therapy, phosphorus-calcium metabolism, anemia.

Pages: 305–310

For citation:

Ortikboev J.O. - OPTIMIZATION OF METHODS FOR PREVENTING THE PROGRESSION OF THE CLINICAL COURSE OF CHRONIC KIDNEY DISEASE//New Day in Medicine 11(85)2025 305-310 https://newdayworldmedicine3d.com/en/new_day_medicine/11-85-2025

List of References

  1. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet . 2020;395(10225):709-733.
  2. Jha V., Garcia-Garcia G., Iseki K., et al. Chronic kidney disease: global dimension and perspectives. The Lancet . 2013;382(9888):260-272.
  3. Levin A., Stevens P.E., Bilous R.W., et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl . 2013;3(1):1-150.
  4. Remuzzi G., Benigni A., Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest . 2006;116(2):288-296.
  5. Drawz P., Rahman M. Chronic kidney disease. Ann Intern Med . 2015;162(11):ITC1-ITC16.
  6. Ruggenenti P., Perna A., Remuzzi G.; GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int. 2003;63(6):2254-2261.
  7. Heerspink H.J.L., Kröpelin T.F., Hoekman J., et al. Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol. 2015;26(8):2055-2064.
  8. Garneata L., Stancu A., Dragomir D., et al. Ketoanalogue-Supplemented Vegetarian Very Low–Protein Diet and CKD Progression. J Am Soc Nephrol. 2016;27(7):2164-2176.
  9. Palmer S.C., Ruospo M., Natale P., et al. Phosphate-binding agents for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev. 2018;8(8):CD006023.
  10. Locatelli F., Nissenson A.R., Barrett B.J., et al. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008;74(10):1237-1240.
Download Full Text (PDF)